Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background. Type 2 diabetes mellitus increases the risk of sarcopenia, which is characterized by decreased muscle mass, strength, and function. However, there are no effective drugs to treat diabetic sarcopenia, and its underlying mechanism remains unknown. Here, we aimed to determine whether the GLP-1 receptor agonist (GLP-1RA) dulaglutide (Dul) affects the progression of diabetic sarcopenia. Methods. db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks. Mouse muscle tissues were then pathologically evaluated and stained with F4/80 or MPO to detect macrophages and neutrophils, respectively. In addition, inflammatory factors and FNDC5 in the muscle tissues were detected using qRT-PCR. Moreover, C2C12 cells were induced to enable their differentiation into skeletal muscle cells, and muscle factor levels were then detected. Furthermore, changes in muscle factor levels were detected at various glucose concentrations (11 mM, 22 mM, and 44 mM). Results. In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice. In vitro, a C2C12 cell differentiation model was established through the observation of cell morphology and determination of myokine levels. Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited. Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein. Conclusions. Treatment with the GLP-1RA dulaglutide protects db/db mice against skeletal muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. High glucose inhibited the differentiation of C2C12 cells and decreased the mRNA and protein levels of myokines. Dulaglutide could reverse the differentiation state induced in C2C12 cells by high glucose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In previous experiments, exendin-4 (Ex-4) inhibited the expression of myostatin (MSTN), atrophy-factor F-box only protein 32 (atrogin-1) and muscle ring finger protein 1 (MuRF-1) in dexamethasone-treated C2C12 myotubes.376–378”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [377]
Experimental — accuracy not yet measuredIn the citing paper
“This occurs despite preclinical evidence suggesting that these agents may exert beneficial effects on skeletal muscle by mitigating obesity-related muscle atrophy, modulating inflammation, and improving muscle fiber composition, size, and lipid distribution [10,11].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
Collins, C. A., Olsen, I., Zammit, P. S., Heslop, L., Petrie, A., Partridge, T. A., & Morgan, J. E. (2005) · Cell · doi:10.1016/j.cell.2005.05.010 · Cited by 1,445
Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102
Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Lee, J. S., Kuller, L. H., Boudreau, R., de Rekeneire, N., Harris, T. B., Kritchevsky, S., Tylavsky, F. A., Nevitt, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0264 · Cited by 778
Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., Kuller, L. H., Broudeau, R., Kammerer, C., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2537 · Cited by 766
Sarcopenia – Molecular mechanisms and open questions
Wiedmer, P., Jung, T., Castro, J. P., Pomatto, L. C. D., Sun, P. Y., Davies, K. J. A., & Grune, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101200 · Cited by 471
Li, C., Yu, K., Shyh‐Chang, N., Li, G., Jiang, L., Yu, S., Xu, L., Liu, R., Guo, Z., Xie, H., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12417 · Cited by 280
Hwang, H., Bowen, B. P., Lefort, N., Flynn, C. R., De Filippis, E. A., Roberts, C., Smoke, C. C., Meyer, C., Højlund, K., Yi, Z., et al. (2010) · Diabetes · doi:10.2337/db09-0214 · Cited by 255
Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00669-4 · Cited by 239
Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
Hong, Y., Lee, J. H., Jeong, K. W., Choi, C. S., & Jun, H. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12434 · Cited by 188
Sarcopenia: a chronic complication of type 2 diabetes mellitus
Trierweiler, H., Kisielewicz, G., Hoffmann Jonasson, T., Rasmussen Petterle, R., Aguiar Moreira, C., & Zeghbi Cochenski Borba, V. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0326-5 · Cited by 172
Chang, J. S., Kim, T. H., Nguyen, T. T., Park, K., Kim, N., & Kong, I. D. (2017) · Geriatrics & Gerontology International · doi:10.1111/ggi.13030 · Cited by 166
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Yoshida, T., Tabony, A. M., Galvez, S., Mitch, W. E., Higashi, Y., Sukhanov, S., & Delafontaine, P. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.035 · Cited by 142
Malafarina, V., Uriz-Otano, F., Malafarina, C., Martinez, J. A., & Zulet, M. A. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.010 · Cited by 131
Aluganti Narasimhulu, C., & Singla, D. K. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12662 · Cited by 106
Ostler, J. E., Maurya, S. K., Dials, J., Roof, S. R., Devor, S. T., Ziolo, M. T., & Periasamy, M. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00277.2013 · Cited by 102
Qiu, S., Cai, X., Yin, H., Zügel, M., Sun, Z., Steinacker, J. M., & Schumann, U. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.006 · Cited by 96
Myokines, physical activity, insulin resistance and autoimmune diseases
Díaz, B. B., González, D. A., Gannar, F., Pérez, M. C. R., & de León, A. C. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.09.002 · Cited by 82
Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels
Rana, K. S., Pararasa, C., Afzal, I., Nagel, D. A., Hill, E. J., Bailey, C. J., Griffiths, H. R., Kyrou, I., Randeva, H. S., Bellary, S., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0627-2 · Cited by 66
Dulaglutide: A Review in Type 2 Diabetes
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01260-9 · Cited by 56 · cited 2×
“As a weekly preparation of GLP1RA, dulaglutide has been benefcial in improving the condition of diabetic patients with chronic kidney disease and cardiovascular disease in clinical trials [18, 19].”
BackgroundBajaj, H. S., Gerstein, H. C., Rao-Melacini, P., Basile, J., Colhoun, H., Conget, I., Cushman, W. C., Dagenais, G. R., Franek, E., Hanefeld, M., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00115-7 · Cited by 56
Borges, T. C., Gomes, T. L. N., Pichard, C., Laviano, A., & Pimentel, G. D. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.05.005 · Cited by 56
Liu, J., Hu, Y., Zhang, H., Xu, Y., & Wang, G. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.020 · Cited by 54
Manickam, R., Tur, J., Badole, S. L., Chapalamadugu, K. C., Sinha, P., Wang, Z., Russ, D. W., Brotto, M., & Tipparaju, S. M. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12887 · Cited by 50
Kamiya, M., Mizoguchi, F., & Yasuda, S. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13025 · Cited by 49
Khin, P. P., Hong, Y., Yeon, M., Lee, D. H., Lee, J. H., & Jun, H.-S. (2021) · Aging · doi:10.18632/aging.203546 · Cited by 37
Kimura, T., Obata, A., Shimoda, M., Hirukawa, H., Kanda‐Kimura, Y., Nogami, Y., Kohara, K., Nakanishi, S., Mune, T., Kaku, K., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.007 · Cited by 37
Guarnotta, V., Bianco, M. J., Vigneri, E., Panto’, F., Lo Sasso, B., Ciaccio, M., Pizzolanti, G., & Giordano, C. (2021) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.015 · Cited by 36
Wang, Y., Deng, F., Zhong, X., Du, Y., Fan, X., Su, H., & Pan, T. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175730 · Cited by 32
Self-citationHu, Q., Mao, W., Wu, T., Xu, Z., Yu, J., Wang, C., Chen, S., Chen, S., Xu, B., Xu, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736640 · Cited by 32 · cited 2×
“An increased expression of TNF-α in myeloid cells impairs their diferentiation [31].”
BackgroundDifferent Resistance-Training Regimens Evoked a Similar Increase in Myostatin Inhibitors Expression
Santos, A., Lamas, L., Ugrinowitsch, C., Tricoli, V., Miyabara, E., Soares, A., & Aoki, M. (2015) · International Journal of Sports Medicine · doi:10.1055/s-0035-1547219 · Cited by 16
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 101
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47
Metadata
- Authors
- Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y.
- Affiliations
- Second Affiliated Hospital of Anhui Medical University (CN)
- Corresponding author
- Wang, Yue
- Pan, Tianrong
- Du, Yijun
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2023-08-07
- Volume
- 2023
- Pages
- 1-10
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC10425251
- OpenAlex
- W4385623415
- Cited by
- 26
- References
- 33
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 7 · 2023: 3
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82200805, 2021lcxk024, 2022xkj033, MBLHJJ202002, MBLHJJ202005)
- Anhui Medical University (82200805, 2021lcxk024, 2022xkj033, MBLHJJ202002, MBLHJJ202005)
- Joint Research Fund for Chronic Disease Prevention and Control (82200805, 2021lcxk024, 2022xkj033, MBLHJJ202002, MBLHJJ202005)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- dulaglutide, GLP-1 receptor agonists, skeletal muscle injury, inflammation, myogenesis, FNDC5, myokines, high glucose, db/db mice, C2C12 myoblasts, interleukin-6, MCP-1, CXCL1, macrophages, neutrophils
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.